Clinical Trial Update: Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B) [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing saxagliptin and metformin (Glucophage) combination formulations in healthy subjects; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glucophage (metformin)
• Saxagliptin (saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2011-01-21